A 109.67 (-5.45%)
US00846U1016Medical Diagnostics & ResearchDiagnostics & Research

Agilent Technologies (A) Competitor Comparison

We are evaluating the key criteria listed to compare Agilent Technologies (A) against its competitors in the Diagnostics & Research industry.

Linearity 3 years - A ranking 5 / 58

These are the competitors of Agilent Technologies in the industry Diagnostics & Research ranked by linearity 3 years
1. Sera Prognostics SERA
113.08
2. Laboratory Corp of America Holdings LH
107.96
3. Anixa Biosciences ANIX
36.91
4. Ortho Clinical Diagnostics Holdings OCDX
33.4
5. Agilent Technologies A
16.48
6. PerkinElmer PKI
16.14
7. Mettler-Toledo MTD
14.5
8. Thermo Fisher Scientific TMO
12.99
9. Waters WAT
11.02
10. NeoGenomics NEO
10.98
11. Syneos Health SYNH
10.68
12. Qiagen QGEN
10.37
13. Danaher DHR
9.94
14. Icon ICLR
8.3
15. Quest Diagnostics DGX
8.17
16. IQVIA Holdings IQV
7.88
17. IDEXX Laboratories IDXX
7.7
18. Heska HSKA
7.67
19. Olink Holding OLK
6.67
20. Twist Bioscience TWST
6.41
21. Exact Sciences EXAS
4.75
22. Global Cord Blood CO
4.22
23. Charles River Laboratories CRL
4.21
24. DexCom DXCM
4.15
25. Sotera Health SHC
3.93
26. Bioventus BVS
3.73
27. National Research NRC
3.56
28. Myriad Genetics MYGN
3.39
29. Guardant Health GH
3.3
30. MaxCyte MXCT
3.27
31. Lantheus Holdings LNTH
3.1
32. Psychemedics PMD
2.88
33. Medpace Holdings MEDP
2.77
34. Exagen XGN
2.61
35. Enzo Biochem ENZ
2.57
36. CareDx CDNA
2.56
37. Neogen NEOG
2.53
38. Pacific Biosciences of California PACB
2.52
39. Biodesix BDSX
2.46
40. Fulgent Genetics FLGT
2.38
41. Illumina ILMN
2.21
42. Personalis PSNL
2.2
43. MDxHealth MDXH
2.16
44. Precipio PRPO
2.04
45. Trinity Biotech TRIB
2
46. Neuronetics STIM
1.98
47. RadNet RDNT
1.9
48. Organovo Holdings ONVO
1.79
49. DarioHealth DRIO
1.79
50. Co-Diagnostics CODX
1.7
51. Interpace Biosciences IDXG
1.68
52. Inotiv NOTV
1.63
53. bioAffinity Technologies BIAF
1.55
54. SeqLL SQL
1.48
55. Prenetics Global PRE
1.41
56. Aspira Womens Health AWH
1.38
57. Meridian Bioscience VIVO
0.73
58. Natera NTRA
0.56

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.